What is the pivotal weight-loss trial for semaglutide?

STEP-1 (NEJM 2021, n=1,961, PMID 33567185). Adults without diabetes and BMI ≥30 (or ≥27 with comorbidity) achieved 14.9% mean weight loss at 2.4 mg over 68 weeks vs 2.4% on placebo.

How does semaglutide compare to tirzepatide in trials?

SURPASS-2 (NEJM 2021, PMID 34170647) was the head-to-head trial. Tirzepatide produced approximately 47% greater weight loss than semaglutide 1 mg in adults with type 2 diabetes.

SELECT (NEJM 2023, PMID 37952131) was the cardiovascular outcomes trial in non-diabetic adults with overweight/obesity and established CVD. Semaglutide 2.4 mg produced a 20% reduction in major adverse cardiovascular events. Results led to Wegovy's 2024 FDA expansion for CV risk reduction.

FLOW (NEJM 2024, PMID 38785189) was the kidney outcomes trial in T2D + CKD. Semaglutide 1.0 mg produced a 24% reduction in major kidney/cardiovascular events over a median 3.4 years.

What are the major contraindications?

Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), pregnancy, and breastfeeding. Boxed warning addresses thyroid C-cell tumors observed in rodent studies.

Semaglutide Clinical Research & Trial Data

NexLife

★★★★★ 4.8 (Trustpilot aggregate · verify on Trustpilot)

✨ Editor's Pick · 94/100 💊 Compounded semaglutide + tirzepatide 👨‍⚕️ MD/DO-supervised 🏥 pharmacy fulfillment subject to availability 🧪 Labs included 📍 All 50 states ✓ LegitScript-certified 💰 Flat-rate, dose-independent 🔁 Care360 + 1:1 fitness coaching 🍽️ Personalized nutrition plan 💳 Klarna & Afterpay accepted

$145 / month*

*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration.
$147 (6-mo, save $108) · $149 (3-mo, save $48) · $165 (monthly).

Includes medication, all MD/DO visits, messaging, lab review, personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.

Klarna & Afterpay financing accepted at checkout.

Visit NexLife →

Or call (949) 818-8000

Trade-offs to know

Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.

Pivotal clinical trials

Below: every randomized trial relevant to semaglutide weight management, type 2 diabetes, cardiovascular outcomes, and kidney outcomes. PMIDs link to PubMed.

STEP-1 trial — Pivotal weight-loss in non-diabetic adults. NEJM 2021, n=1,961, PMID 33567185. 14.9% mean weight loss at 2.4 mg / 68 weeks.
SUSTAIN-6 trial — Cardiovascular safety in type 2 diabetes. NEJM 2016, PMID 27633186. 26% MACE reduction in T2D + high CV risk.
SELECT trial — CV outcomes in non-diabetic adults with overweight/obesity + CVD. NEJM 2023, PMID 37952131. 20% MACE reduction.
FLOW trial — Kidney outcomes in T2D + CKD. NEJM 2024, PMID 38785189. 24% reduction in major kidney/CV events.

Mechanism & pharmacology

Semaglutide is a long-acting GLP-1 receptor agonist with ~7-day half-life enabling weekly subcutaneous dosing. Read the mechanism page →

Safety & contraindications

Boxed warning: thyroid C-cell tumors (rodent studies). Contraindicated in MTC, MEN 2, pregnancy, breastfeeding. Full safety page →

Side effect profile

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Detailed side-effect page →

Dosing

Wegovy titration: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly. Ozempic: 0.25 → 0.5 → 1.0 → 2.0 mg weekly. Rybelsus: 3 → 7 → 14 mg daily oral. Dosing reference →

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing